Press Release PR9.NET
Home Submit Press Release Search Archives
Press Release
Advanced Search
BROWSE BY CATEGORY

Health Health
Organizations
Dentistry, Education
Insurance, Medicine
Mental, Nutrition
Environmental Health
Resources, Weight Loss

Business Business
Computers Computers
Entertainment Entertainment
Games Games
Home Home
Science Science
Sports Sports
Society Society
Teens Teens
Press Release Category Health - Medicine - Med Services Europe B.V. Release Date: February 07, 2005

Generating Pharmaceutical Sales before Marketing Authorization


By Med Services Europe B.V.
February 07, 2005
Send SEND Print PRINT Download PDF Version PDF Contact Med Services Europe B.V. CONTACT

When a patient has a serious illness and there is no approved drug available, the physician may want to try one which has not been authorized for marketing. This presents drug-makers with an opportunity to generate revenues while development is still in-progress

PR9.NET February 07, 2005 - When a patient has a serious illness and there is no approved drug available, the physician may want to try one which has not been authorized for marketing by national health authorities but has shown promise in clinical trials. European Named Patient Programs, like US compassionate use programs, offer physicians access to pharmaceuticals which have not yet been licensed. However, there is one important difference: in Europe an unlicensed drug can be reimbursed. This presents drug-makers with an opportunity to generate revenues while development is still in-progress.

Significant Revenues Are Possible

The additional revenues can be considerable. For example, Pharmion, a US based company focusing on Oncology and Hematology reported dramatic increases in its Thalidomide sales from $1.9 million in 2Q ‘03 to $15.3 million in 2Q ‘04, primarily due to named patient sales in Europe for Multiple Myeloma. Thalidomide sales accounted for approximately 75% of Pharmion’s total revenues for the first half of 2004, according to company sources, and were generated while the product awaits marketing approval for this indication. Before receiving European Marketing Approval, Shire’s Argylin® for essential thrombocythaemia generated about 5% of its total sales from its European named patient program.

Other Benefits of Named Patient Programs

A named patient program can speed uptake after official launch. Physicians, who have had experience before launch, via clinical trials or named patient programs, often become early adopters and references for other physicians once the drug is freely circulating.

Named patient programs, like US compassionate use programs, can increase good-will toward the company because they simplify the process of gaining access for patients in critical need. Smaller companies often can not afford the administrative time and costs of shipping drugs around the world before launch. This can lead to frustration and resentment towards a company that many physicians will remember long after a drug is officially on the market. Creating a formal channel eliminates the unfortunate need of denying requests and risking ill-will later.

A named patient program should be considered an important part of a pre-launch program. It increases awareness to a pharmaceutical’s existence, creates excitement, generates good-will and speeds penetration of the product after launch.

Frequent Communication is Necessary

If one of the objectives is to generate revenues, setting up a named patient program is just the beginning. In order to achieve success, physicians need to be aware of the product and what they need to do to get it. Typical methods of informing physicians, such as sales rep visits and ads, may not be appropriate because a license is necessary to market a drug. While physicians are used to simply writing a prescription and being done with it, named patient programs require paper-work that some find tedious. Therefore the company needs to create an appropriate communication plan and work closely with the targeted medical community to keep them informed and simplify the process.

Issues to Consider

You have decided to make a named patient program part of your pre-marketing plan, what now?

If you do not have an experienced European marketing group, an organization that is familiar in sales and marketing of pharmaceuticals in Europe can help you to maximize participation in the named patient program. A communication plan, if properly developed and implemented can increase product awareness, but communication concerning an unlicensed product must be done appropriately. This plan should ensure that your entire target group:

• Is fully aware of the product AND the program
• Knows what needs to be done to take advantage of the program
• Has an advocate available to guide them through the process


The Author, Dr Gene Emmer, is President of Med Services Europe B.V., a European-based consultancy. Med Services Europe conducts business development for Pharmaceutical, Diagnostic, Biotech and Medical Equipment manufacturers. We specialize in building and managing distributor networks for medical manufacturers in Eastern and Western Europe. www.MedServicesEurope.com


# # #

Contact Information of Med Services Europe B.V. Contact Information of Med Services Europe B.V.
Phone +41764249963
Website http://www.NewDisability.com
E-Mail E-mail Address Protected


About Med Services Europe B.V.

About the Author: Dr. Gene Emmer is President of Med Services Europe (http://www.NewDisability.com).

Recent News Headlines
More Press Releases
Industry Category of Current Press Release
    Copyright © 2004 - 2014 PR9.NET - All rights reserved RSS Feeds Submit Press Release Terms of Service Privacy Policy